Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Gross Margin (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Gross Margin for 2 consecutive years, with 80.0% as the latest value for Q2 2025.

  • Quarterly Gross Margin changed N/A to 80.0% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 125.0% through Dec 2025, changed N/A year-over-year, with the annual reading at 73.4% for FY2025, N/A changed from the prior year.
  • Gross Margin for Q2 2025 was 80.0% at Mereo BioPharma, down from 127.3% in the prior quarter.
  • The five-year high for Gross Margin was 127.3% in Q4 2023, with the low at 61.89% in Q2 2023.